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Isotretinoin alleviates renal damage in rat chronic glomerulo- network of factors that are involved in glomerular cell
nephritis. proliferation, inflammation and extracellular matrix for-
Background. Retinoids, derivatives of vitamin A, have strong mation [1]. In that respect, retinoids, which are deriva-anti-inflammatory and antiproliferative properties. We previ-
tives of vitamin A, exhibit a number of potentially bene-ously demonstrated that the pan-agonists all-transretinoic acid
(RA) and isotretinoin (13-cis RA) alleviate renal damage in ficial effects such as antiproliferative, anti-inflammatory,
rat acute glomerulonephritis (GN) induced by anti-Thy-1.1 antimigratory and antifibrogenic actions [2–4]. Retinoic
mAb OX-7. acids (RA), unlike retinol (vitamin A), act via specificMethods. The present study examined the effects of low
receptors, that is, retinoid A (RAR) and retinoid X re-dose and high dose treatment with isotretinoin in the chronic
ceptor (RXR) with the subtypes , , . These receptorsglomerulonephritis model, Thy-GN. Thy-GN was induced by
a single intravenous injection of monoclonal antibody (mAb) are expressed in the rat and human kidney [5, 6]. Reti-
1-22-3 in uninephrectomized Wistar rats (N  7 to 10 per noid receptors belong to the superfamily of ligand-acti-group). Control and nephritic groups were treated with vehicle
vated nuclear receptors that include vitamin D, thyroid(veh), low dose isotretinoin (2 mg/kg body wt), or high dose
receptor and peroxisome-proliferator-activated receptorisotretinoin (10 mg/kg body wt). The experiment was termi-
nated 60 days after induction of Thy-GN. (PPAR) [7]. These receptors have a role in kidney devel-
Results. In animals with Thy-GN, isotretinoin abrogated the opment, since double knockout mice with functionallyincrease in blood pressure and significantly reduced albumin-
inactive retinoid receptors are characterized by renaluria. Glomerulosclerosis index, glomerular and interstitial cell
aplasia or loss of the renal bud [8–10]. In the adult animalcounts, as well as the area of the interstitial space were signifi-
cantly lower in nephritic rats treated with low and high dose iso- retinoids are involved in cellular differentiation and con-
tretinoin compared to vehicle-treated nephritic controls. Treat- trol of proliferative and inflammatory processes [11, 12].ment with isotretinoin also significantly reduced the number of
These receptors regulate expression of target genes di-glomerular and interstitial macrophages. The increase of trans-
rectly via binding to retinoic acid response elements [13],forming growth factor (TGF)-1, TGF receptor II and prepro-
endothelin-1 gene expression in vehicle-treated nephritic rats which are often located on the promoters of genes in-
was significantly attenuated by isotretinoin. volved in extracellular matrix production and degradation.
Conclusions. Treatment with isotretinoin significantly reduces
Alternatively, retinoids may act indirectly via inhibitionglomerular and interstitial damage in rats with chronic glomer-
of transcription factors such as activator protein-1 (AP-1)ulonephritis as indicated by different functional and histologi-
cal markers. Retinoids may provide a novel therapeutic option [14, 15], nuclear factor-B (NF-B) [16, 17] or cAMP-
for the treatment of glomerulonephritis. responsive binding element binding protein (CREB)
[18], and others whose roles in renal disease are cur-
rently evolving.In the treatment of progressive renal disease, the focus
We have previously demonstrated that in the early re-of research has shifted to some extent from blood pres-
pair phase of experimental mesangioproliferative glo-sure control toward therapeutic interference with the
merulonephritis of the rat, all-trans RA and isotretinoin
limit glomerular cell proliferation, reduce immigration
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of monocytes, macrophages and reduce the expression ofrenal damage, renoprotection, interstitial damage, progressive renal
disease. growth factors such as platelet-derived growth factor-B
(PDGF B) or transforming growth factor-1 (TGF-1)Received for publication February 7, 2001
[19, 20]. Retinoids were shown to inhibit the prolifera-and in revised form June 13, 2001
Accepted for publication July 17, 2001 tive response of vascular smooth muscle cells to angio-
tensin II via an activator protein-1 (AP-1) related mecha- 2001 by the International Society of Nephrology
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nism [21]. The operation of a similar mechanism in vivo daily and the high dose was 10 mg/kg BW per day. Treat-
ment was started one day after injection of the antibody.is suggested by the observation that retinoids reduce
glomerular c-fos expression in the nephritic kidney. Reti-
Galenic preparation of isotretinoinnoids significantly reduced renal damage as indicated by
To improve homogeneity and oxidative stability, iso-a reduced capillary occlusion score and a marked reduc-
tretinoin (F. Hoffmann-La Roche Ltd, Basel, Switzerland)tion in albuminuria.
was first incorporated into a lactose-gelatin granular car-Such beneficial effects in an acute model of glomerulo-
rier substance including 5% ascorbic acid (Sigma-Aldrichnephritis do not provide information, if retinoids are
Chemie, Deisenhofen, Germany) using the wet-granu-effective when given over a prolonged period of time.
lation method [28]. For preparation of the carrier sub-To address this issue, we examined the effects of two
stance an oscillating damp-granulating machine was ap-different doses of isotretinoin in the chronic model of
plied (Frewitt). Subsequently, the isotretinoin carrierrat mesangioproliferative glomerulonephritis using the
was pressed into standard rat chow (Altr. 1324; Altromin,monoclonal antibody (mAb) 1-22-3 in uninephrectom-
Lage, Germany). The chow of vehicle rats consisted ofized rats [22–25], an established model of chronic mesan-
a carrier substance including 5% ascorbic acid incorpo-gioproliferative glomerulonephritis [26, 27].
rated into standard rat chow without isotretinoin. The
isotretinoin carrier substance was produced with the
METHODS friendly support of Dr. M. Bultmann of the Institute of
Pharmaceutical Technology, University of Heidelberg.Induction of chronic glomerulonephritis
Rat chow was stored in portions, packed in vacuum-Male Wistar rats weighing 170 to 190 g (Charles River,
ized light-tight sealed plastic bags at 20C. Rats wereSulzfeld, Germany) were used in this study. The rat anti-
fed after 6 p.m. when lights were turned off in the animalThy 1.1 model of chronic mesangioproliferative glomeru-
facility.lonephritis (Thy-GN) was induced by a single intrave-
Animals were pair-fed to ascertain comparable calorienous injection of 0.5 mg mAb 1-22-3 into rats one hour
and isotretinoin intakes in nephritic animals and non-after unilateral nephrectomy [22, 23] . Monoclonal anti-
nephritic controls and adjusted per os by offering thebody 1-22-3 was dissolved in phosphate-buffered saline
amount of pellets calculated to deliver the respective(PBS) as previously described [25]. Unilateral nephrec-
dose. The rats had free access to tap water.tomy was performed under anesthesia by injection of
100 mg/kg body weight (BW) intramuscularly (IM) Keta- Blood pressure measurement
mine (Ketanest, Parke-Davis, Freiburg, Germany) and Systolic blood pressure (SBP) was determined on day 0,
5 mg/kg BW IM Xylazine (Rompun, Bayer, Leverkusen, week 3, week 6, week 7 and week 8 after the induction
Germany). A small flank incision was made, the right of nephritis by tail cuff plethysmography under light ether
adrenal gland and renal capsule were separated from anesthesia. The SBP for each rat was calculated as the
right kidney, the right renal artery, vein and ureter were average of three separate measurements at each session.
ligated at the renal pedicle and the kidney was removed.
All rats were uninephrectomized. Animal experimenta- Measurement of urinary albumin and
tion was performed in accordance with the German ani- creatinine clearance
mal protection laws. The experiment was terminated 60 For determination of albumin in urine, rats were placed
days after induction of glomerulonephritis. Treatment in metabolic cages and urine was collected for 24 hours.
was started one day after injection of the antibody. Urine was frozen at20C until measurement. Albumin-
uria in rats was determined essentially as in the study ofExperimental groups
Magnotti et al [29] on a 96-well ELISA-plate using a
Animals were randomly allocated to six experimental peroxidase-conjugated anti-rat-albumin-antibody (ICN-
groups: Group 1, uninephrectomized vehicle (Control/ Biomedical, Eschwege, Germany). Measurements were
Vehicle), N  7; Group 2, uninephrectomized  low performed in quadruplicate.
dose isotretinoin (Control/Iso-low), N 6; Group 3, uni- Creatinine clearance was calculated after enzymatic
nephrectomized  high dose isotretinoin (Control/Iso- determination of serum and urinary creatinine (from a
high), N 7; Group 4, uninephrectomized 0.5 mg mAb 24-hour urine collection 24 hours before the animals were
1-22-3 vehicle (Thy-GN/Vehicle), N 7; Group 5, uni- sacrificed; Creatinine Kit, Hoffmann La Roche, Basel,
nephrectomized  0.5 mg mAb 1-22-3  low dose isotre- Switzerland) on a Hitachi autoanalyzer.
tinoin (Thy-GN/Iso-low), N  9; Group 6, uninephrec-
Processing of renal tissuetomized  0.5 mg mAb 1-22-3  high dose isotretinoin
(Thy-GN/Iso-high), N  10. For sacrifice, animals were injected with Xylazine (5 mg/
kg BW IM; BayerVital, Leverkusen, Germany) and Ket-The low dose of isotretinoin was 2 mg/kg BW per os
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amine 10% (100 mg/kg BW IM; WDT, Garbsen, Ger- ford, UK) and a goat-anti-rat collagen I antibody (Dia-
nova). Before incubating with primary antibodies againstmany). Rats were saline-perfused containing 0.5 g/L pro-
caine hydrochloride at a defined pressure of 110 mm Hg KI-67 microwave pre-treatment was performed in citrate
buffer (pH 6.0) for 3 	 3 minutes (750 W). For staining,by retrograde insertion of a cannula into the abdominal
aorta [30]. The kidneys were removed immediately, the labeled avidin-biotin method and 3-amino-9-ethyl-
carbazole (AEC) as substrate were applied using the His-and further processed for histological studies and RNA
extraction. tostain-SP kit (Zymed, San Francisco, CA, USA) accord-
ing to the manufacturer’s recommendations. Sections were
Renal morphology counterstained with Mayer’s hemalum (Merck, Darm-
stadt, Germany) and mounted under glass coverslips.Tissue for light microscopy was fixed in 10% buffered
formalin and embedded in paraffin. Sections of 4
m thick- For each biopsy 20 cross sections of consecutive corti-
cal glomeruli with a diameter of at least 100 
m wereness were stained with the periodic acid-Schiff (PAS)
reagent and counterstained with hematoxylin. The inves- evaluated. Mean values per glomerular cross sections
were calculated for the number of proliferating (KI-67)tigator was unaware of the treatment protocol in all
morphological determinations. cells and monocytes/macrophages (ED-1). For evalua-
tion of monocytes/macrophages interstitial cross-sec-Glomerular sclerosis index (GSI). A semiquantitative
score was used to evaluate the degree of glomerular tions were analyzed using a grid containing 121 fields
(Leica, Wetzlar, Germany). In each kidney, at least 20sclerosis according to the method of Raij, Azar and
Keane [31]. The severity of the lesions was examined in non-overlapping cortical areas of two different sections
were evaluated. In immunoperoxidase stains for fibro-30 glomeruli selected at random, graded from 0 to 4
points according to the percentage of morphological nectin and collagen I, 20 glomeruli and 20 non-overlap-
ping cortical areas were graded semiquantitatively ac-changes on each glomerulus and assigned a score begin-
ning with 0  0%, 1  1-25%, 2  26 to 50%, cording to the intensity of immunostaining: no staining
(grade 0), faint (grade 1), moderate (grade 2), intense3  51 to 75%, and 4  76 to 100%. The number
of glomeruli showing a lesion of 0 was n0, of 1 n1, of (grade 3) or maximal (grade 4) staining.
2 n2, of 3 n3, of 4n4, respectively. Thirty glomeruli
RNA isolation and reverse transcriptionwere examined independently, and the GSI was obtained
by the following formula: (0 	 n0  1 	 n1  2 	 n2  The Trizol (Life Technologies, Grand Island, NY, USA)
method was used for RNA isolation according to the3 	 n3  4 	 n4)/30.
The tubulointerstitial lesions score was evaluated ac- manufacturer’s recommendations. RNA was checked for
degradation of total RNA on 1% agarose gel. RNAcording to the method of Veniant et al [32]. At least 20
non-overlapping cortical areas were examined using a concentrations were determined by spectrophotometric
measurements at wavelengths of 260/280 nm. Reversegrid containing 121 fields (Leica, Wetzlar, Germany).
Total glomerular cell count. The total glomerular count transcription was performed as described elsewhere [36].
For each biopsy reverse transcription was carried outwas determined in PAS-stained sections in 30 cortical
glomeruli per kidney with a diameter of at least 100 
m three times and the resulting cDNA was pooled.
and the mean number of cells per glomerulus was calcu-
Quantitative polymerase chain reaction assaylated [33].
Interstitial space and cells. For evaluation of intersti- Quantification of specific mRNAs was performed es-
sentially as described by Paul, Wagner and Dzau [37] andtial space and number of interstitial cells PAS staining
was performed. Cross-sections were analyzed using a Wagner et al [36]. For each gene, a DNA deletion mu-
tant was cloned exhibiting the same sequences as the en-grid containing 121 fields [34, 35]. In each kidney, at
least 20 non-overlapping cortical areas of two different dogenous genes with identical primer binding sites, but
a deletion of maximally 20% resulting in a shorter ampli-sections were evaluated. The proportion of interstitial
versus tubular area was quantified and the number of fication product [38]. Reverse-transcribed (RT) RNA
(0.1 
g) was used for amplification in the presence ofinterstitial cells per grid was counted.
defined concentrations of DNA deletion mutants as in-
Immunohistochemistry ternal standards. The concentration of standard DNA was
selected to allow comparable degrees of amplificationRenal tissue was fixed in 10% buffered formalin
(KI-67, fibronectin) or methyl Carnoy’s solution (ED-1, of wild type and mutant genes. Primers were used for
TGF-1, 5-CAC CAT CCA TGA CAT GAA CC-3collagen I), paraffin-embedded and cut into 4 
m slices.
The primary antibodies were a mouse anti-rat KI-67 (sense primer) and 5-TCA TGT TGG ACA ACT GCT
CC-3 (antisense), for TGF receptor II, 5-CTA CAAantibody (Dianova, Hamburg, Germany), a rabbit-anti-
rat fibronectin antibody (Chemicon, Temecula, CA, GGC CAA GCT GAA GC-3 (sense) and 5-AGC CAT
GGA GTA GAC ATC CG-3 (antisense) [39], for pre-USA), a mouse-anti-rat ED-1 antibody (Serotech, Ox-
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pro-endothelin-1 5-TGG CTT TCC AAG GAG CTC presence of either low dose (1.2  0.1 mL/min/kg BW)
or high dose (1.5  0.2 mL/min/kg BW) isotretinoinC-3 (sense) and 5-GCT TGG CAG AAA TTC CAG
C-3, and for fibronectin 5-AGG ATT CCG AGT GGA treatment in nephritic rats compared to the vehicle-
treated group.GTA CG-3 (sense) and 5-AGG AGG TGT CCA CAT
GAT GG-3 (antisense). After 60 days, 24 hour albuminuria was 5 mg/day in
vehicle-treated nephritic rats compared to 0.3 mg/dayThe polymerase chain reaction (PCR) reaction mix
contained 0.25 mmol/L deoxynucleoside triphosphate in non-nephritic controls (Fig. 1C). Similar albuminuria
values were obtained at weeks 3 and 5 in vehicle-treated(dNTP; Promega, Madison, WI, USA), 2.5 mmol/L
MgCl2, 20 mmol/L Tris-HCl (pH 8.4), 50 mmol/L KCl, nephritic rats (P  0.01, data not shown). In nephritic
animals treated with low or high dose isotretinoin, albu-80 nmol/L levels sense and antisense primers (Life Tech-
nologies,) and 1 U of Taq DNA Polymerase (GIBCO minuria was significantly less (Fig. 1C).
Life Technologies, Paisley, UK). The thermal profile
Effects of isotretinoin on glomerular damageused consisted of denaturation at 94C for one minute,
annealing at 55C for one minute, and extension at 72C Figure 2 depicts typical PAS-stains of glomeruli of
vehicle-treated non-nephritic (Fig. 2A) and nephritic ratsfor one minute carried out 31 times for TGF-1, 26 times
for TGF receptor II, 31 times for prepro-ET-1 and 27 that were treated with vehicle (Fig. 2B) or low dose
isotretinoin (Fig. 2C). Note the reduction in mesangialtimes for fibronectin. In all experiments possible contam-
ination with genomic DNA was excluded by PCR-ampli- cell proliferation and mesangial matrix expansion in iso-
tretinoin-treated rats.fication in absence of reverse transcriptase. Amplification
products were separated by agarose gel electrophoresis The glomerulosclerosis index was significantly higher
in vehicle-treated nephritic rats than in non-nephriticand then digitized using a gel documentation system
(Intas, Go¨ttingen, Germany) and Scion Image (NIH, controls. Isotretinoin had no significant effect in non-
nephritic controls, but almost normalized the glomerulo-Bethesda, MD, USA). The ratio between the optical
density of the endogenous cDNA and the optical density sclerosis index in nephritic rats treated with either low
or high dose isotretinoin (Fig. 3A). The total glomerularof the mutant DNA (ODR) was determined. Each sam-
ple was measured in triplicate of individual PCR assays cell number was not affected by isotretinoin-treatment in
non-nephritic controls as compared to the vehicle group.for each gene [40].
In vehicle-treated nephritic rats the glomerular cell num-
Statistical analysis ber was markedly higher and was normalized in nephri-
tic rats treated with either low or high dose isotretinoinAll results are presented as mean values  SEM. The
statistical significance was evaluated by analysis of vari- (Fig. 3B). Glomerular cell proliferation as indicated by
the number of Ki67() glomerular cells was slightly,ance (ANOVA) and Bonferroni’s Multiple Comparison
Test, and significance was accepted at P  0.05. but significantly higher in vehicle-treated nephritic rats,
but was not significantly different from controls in ne-
phritic rats treated with either low or high dose isotreti-
RESULTS
noin (Fig. 3C). Glomerular staining for ED-1 positive
Effects of isotretinoin treatment on blood pressure, cells showed significantly more glomerular ED-1() cells
body weight, creatinine clearance and albuminuria in vehicle-treated nephritic rats than in non-nephritic
controls. ED-1 () cells were significantly less in ne-Throughout the experimental period systolic blood
pressure was significantly higher in vehicle-treated glom- phritic rats treated with either low or high dose isotreti-
noin compared to the vehicle-treated group (Fig. 3D).erulonephritic rats than in non-nephritic control rats
(Fig. 1A). Treatment with isotretinoin had no significant
Effects of isotretinoin on tubulointerstitial damageeffect on blood pressure in non-nephritic controls. Ne-
phritic rats treated with either low or high dose isotreti- The tubulointerstitial lesions score was slightly, but
significantly higher in vehicle-treated nephritic rats thannoin, however, had significantly lower blood pressure
levels than vehicle-treated nephritic rats. In isotretinoin- in non-nephritic controls. Treatment either with low or
high dose isotretinoin significantly reduced the tubulo-treated nephritic rats blood pressure was not significantly
different from control (Fig. 1A). interstitial lesions in nephritic rats (Fig. 4A).
Figure 4B indicates that the number of interstitial cellsBody weights of the animals increased throughout the
experiment, but were similar in animals treated with low was significantly higher in vehicle-treated nephritic rats
compared to non-nephritic controls. Neither dose of iso-or high dose isotretinoin or vehicle (Fig. 1B).
Creatinine clearance was not significantly changed in tretinoin had an effect on interstitial cell number in non-
nephritic rats, but in nephritic rats treated with low orvehicle-treated nephritic rats (1.4 0.14 mL/min/kg BW)
compared to non-nephritic control rats (1.3  0.2 mL/ high dose isotretinoin the interstitial cell numbers were
significantly lower compared to those in the vehicle group.min/kg BW). Creatinine clearance was not altered in the
Fig. 1. Effects of isotretinoin treatment on
blood pressure, body weight and albuminuria.
(A) Time course of systolic blood pressure
(BP). Isotretinoin treatment prevented the
blood pressure increase in anti-Thy1.1-nephri-
tis (Thy-GN). Data are presented as mean 
SEM. **P 0.01, ***P 0.001 vs. Con/Vehi-
cle and §§P  0.01, §§§P 0.001 vs. Thy-GN/
Vehicle. Symbols are () Thy-GN/Vehicle;
() Control/Vehicle; () Thy-GN/Iso-low;
() Thy-GN/Iso-high. (B) Time course of
body weight. Body weights were measured
weekly. No significant differences were found
between the groups. Symbols are: () Con-
trol/Vehicle; () Control/Iso-low; () Con-
trol/Iso-high; () Thy-GN/Control; () Thy-
GN/Iso-low; () Thy-GN/Iso-high. Data are
presented as mean SEM. (C ) Twenty-four–
hour albumin excretion (mg/24 h) at day 60.
Treatment of nephritic rats with low and high
dose isotretinoin reduces albumin excretion
by 77 or 70%, respectively. Similar findings
were found at days 21 and 35. Data are pre-
sented as mean  SEM.
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Fig. 2. Representative examples of PAS-stains of glomeruli and immunostaining for monocytes/macrophages (ED-1 positive) in tubulointerstitial
areas. Panels A to C show typical PAS-stains of glomeruli of vehicle-treated non-nephritic (A) or nephritic rats (B) or low-dose isotretinoin-
treated nephritic rats (C ). Note the reduction of mesangial cell proliferation and mesangial matrix expansion in low-dose isotretinoin-treated
animals. Panels D to F depict monocytes/macrophages (positive staining for ED-1) in interstitial areas of vehicle-treated non-nephritic rats (D)
and nephritic rats, which were treated with vehicle (E) or low-dose isotretinoin (F ); ED-positive staining was reduced in nephritic rats with low-
dose isotretinoin treatment.
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Fig. 3. Effects of isotretinoin on glomerular damage. (A) Glomerulosclerosis index (GSI). There was a significant reduction of GSI by treatment
with both high and low dose isotretinoin in rats with Thy-GN. The score was not affected in control rats. Data are presented as mean  SEM.
(B) Glomerular cell count. Isotretinoin reduced total glomerular cell numbers in rats with anti-Thy1.1-nephritis. Cell numbers were significantly
elevated in vehicle-treated nephritic rats as compared to controls. (C ) Proliferating glomerular cells (Ki67 positive). The number of Ki67 positive
glomerular cells was significantly lower in nephritic rats treated with low or high dose isotretinoin than in vehicle-treated rats. (D) Glomerular
monocytes/macrophages (positive staining for ED-1). In vehicle-treated nephritic rats increased glomerular infiltration by monocytes/macrophages
was detected as compared to controls. Infiltration of monocytes/macrophages was significantly lower in nephritic rats with low or high dose
isotretinoin.
The area of the renal interstitium (given as percent of treated non-nephritic (Fig. 2D) or nephritic rats (Fig. 2E)
or low dose isotretinoin-treated nephritic rats (Fig. 2F).grid area) was significantly higher in nephritic rats in
comparison to non-nephritic animals. In nephritic rats
Effects of isotretinoin on expression of genes involvedtreated with either low or high dose isotretinoin, intersti-
in renal damagetial area was significantly smaller (Fig. 4C).
The number of interstitial ED-1 positive cells was sig- Renal cortical expression of TGF-1 was significantly
nificantly higher in nephritic animals as compared to enhanced in vehicle-treated nephritic rats compared to
non-nephritic controls. In nephritic animals treated eithernon-nephritic controls. Either dose of isotretinoin almost
normalized interstitial ED-1 positive cell counts in ne- with low or high dose isotretinoin renal expression of
TGF-1 was almost completely normalized. No effect ofphritic rats (Fig. 4D).
Figure 2 D through F show representative examples of isotretinoin treatment on renal TGF-1 gene expression
was observed in non-nephritic controls (Fig. 5A). Simi-ED-1 immunostains of tubulointerstitial areas in vehicle-
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Fig. 4. Effects of isotretinoin on tubulointerstitial damage. (A) There was a significant reduction of tubulointerstitial lesions score by treatment
with both high and low dose isotretinoin in rats with Thy-GN. The score was not affected in control rats. Data are presented as mean  SEM.
(B) Interstitial cell counts were twofold higher in nephritic rats compared to non-nephritic controls. The number of interstitial cells was significantly
less after treatment with isotretinoin. (C ) In the vehicle-treated nephritic group, the interstitial area was significantly expanded compared to non-
nephritic controls. In contrast, the interstitial area was significantly smaller in nephritic rats treated with low or high dose isotretinoin. (D)
Monocytes/macrophages in the interstitium (positive ED-1 staining). The number of interstitial ED-1 positive cells was markedly higher in nephritic
rats as compared to non-nephritic controls. Isotretinoin limited the increase in interstitial ED-1 positive cells in nephritic rats.
larly renal cortical TGF receptor II mRNA was higher cantly lower (P  0.001) in nephritic rats treated either
with low or high dose isotretinoin. The values were com-in the renal cortex of nephritic rats treated with vehicle,
than in non-nephritic controls. TGF receptor II gene parable to those in non-nephritic vehicle-treated controls
(Fig. 5C).expression was lower in nephritic rats treated with either
low or high dose isotretinoin, but this difference failed
Fibronectin and collagen I immunostainingto reach statistical significance in the high dose group. No
isotretinoin effects were found in non-nephritic controls Glomerular fibronectin immunostaining was very low
in vehicle- and isotretinoin-treated kidneys of non-nephri-(Fig. 5B).
Renal cortical prepro-endothelin-1 gene expression tic rats. Immunostaining was markedly higher in glomer-
uli of vehicle-treated nephritic rats than in non-nephriticalso was significantly higher in vehicle-treated nephritic
rats compared to non-nephritic controls (P  0.001). controls. It was less in nephritic rats treated either with
low or high dose isotretinoin (Fig. 6A).Renal prepro-endothelin-1 gene expression was signifi-
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The immunostaining for fibronectin in the tubulo-
interstitial space was significantly enhanced in vehicle-
treated nephritic rats compared to non-nephritic controls.
It was significantly reduced and essentially normalized
by treatment with either low or high dose isotretinoin
in nephritic rats (Fig. 6B).
Glomerular immunostaining of collagen I protein was
markedly higher in vehicle-treated nephritic rats when
compared to non-nephritic controls. Collagen I immuno-
staining was significantly less in glomeruli of nephritic
rats treated with either dose of isotretinoin (Fig. 6C).
The tubulointerstitial staining for collagen I was mark-
edly higher in nephritic rats than in non-nephritic con-
trols. Significantly less staining was found in the tubulo-
interstitial space of nephritic rats after treatment with
either dose of isotretinoin (Fig. 6D).
DISCUSSION
The data document that isotretinoin lowers albumin-
uria and glomerulosclerosis in a rat model of chronic mes-
angioproliferative glomerulonephritis. These data indicate
that retinoids are not only effective in short term, but
also in long-term models of inflammatory renal damage,
which are more akin to glomerulonephritis in humans.
The model of chronic mesangioproliferative glomeru-
lonephritis in the rat is well established. Cheng et al ob-
served that uninephrectomized rats treated with a single
injection of mAb 1-22-3 developed hypertension, mas-
sive proteinuria and severe glomerular injury [23]. We
confirmed these findings with respect to hypertension
and glomerulosclerosis. With regard to albuminuria, we
saw no progressive increase and it remained stably ele-
vated over the entire experimental period. In contrast,
in the acute nephritic model, urinary albumin excretion
rates of up to 30 mg/day were reported [19]. The reasons
for the more benign course in the present study are not
entirely clear, but may reflect different genetic back-
grounds of the experimental animals or different effi-
ciencies of the antibody preparations. The milder course
of chronic glomerulonephritis also was reflected by the
lack of a reduction in creatinine clearance in vehicle-
treated nephritis rats compared to non-nephritic con-
trols, which also has been described for serum creatinine
change of TGF-1 expression was observed in control rats. Data are
presented as mean  SEM. (B). TGF receptor II mRNA expression
in the renal cortex was significantly less in the low dose, but not in the
high dose isotretinoin-treated group. TGF receptor II gene expression
was significantly higher in nephritic rats in presence of vehicle than that
in the respective non-nephritic group. (C ) Renal cortical expression of
Fig. 5. Renal gene expression of TGF-1, TGF receptor II, and prepro- prepro-endothelin-1 was significantly higher in vehicle-treated nephritic
endothelin-1. (A) TGF-1 mRNA in the renal cortex was significantly rats compared to non-nephritic controls. Both high and low dose isotreti-
elevated in nephritic rats compared to non-nephritic controls. Isotreti- noin completely normalized renal expression of prepro-endothelin-1 in
noin suppressed cortical TGF-1 over-expression in nephritic rats. No nephritic groups.
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Fig. 6. Staining score for extracellular matrix proteins. (A) Glomerular fibronectin immunostaining. Significantly less staining was found in glomeruli
of nephritic rats after treatment with either dose of isotretinoin. The staining for fibronectin was markedly higher in nephritic rats than in non-
nephritic controls. (B) Tubulointerstitial fibronectin immunostaining. Immunostaining was markedly higher in tubulointerstitial areas of vehicle-
treated nephritic rats than in non-nephritic controls. It was significantly less in nephritic rats treated either with low or high dose isotretinoin. (C )
Glomerular collagen I immunostaining. The immunostaining for collagen I in glomeruli was significantly reduced by treatment with either low or
high dose isotretinoin in nephritic rats. In vehicle-treated nephritic rats strong staining was found in contrast to the faint staining of vehicle-treated
control rats. (D) Tubulointerstitial collagen I immunostaining. Tubulointerstitial immunostaining of collagen I protein was markedly higher in vehicle-
treated nephritic rats when compared to that in non-nephritic controls. Collagen I immunostaining was significantly less in the tubulointerstitial area
of nephritic rats treated with either dose of isotretinoin compared to vehicle-treated nephritic rats.
by Kawachi et al in the chronic model [24]. The decrease As in acute anti-Thy1.1-nephritis, isotretinoin reversed
the blood pressure increase in vehicle-treated nephriticin albuminuria by treatment with isotretinoin is not due
to a decrease in glomerular filtration rate, since creati- rats. So far the effects of retinoids on blood pressure
have not been reported to our knowledge. The antihy-nine clearance is not diminished in presence of either
dose of isotretinoin both in non-nephritic controls and pertensive effect is, however, not specific for isotretinoin,
since in the anti-Thy1.1-nephritis model all-trans RAin nephritic rats. The beneficial effects of isotretinoin
are not due to interference with the early immunologic or Ro257386, a retinoid X receptor-specific compound,
lowered blood pressure as well. The exact mechanisminjury: In acute-anti-Thy1.1-nephritis, institution of reti-
noid treatment 3 days before (pre-treatment) or after of a retinoid-mediated decrease of blood pressure has
not been clarified. The effect may be non-specific andinjection (post-treatment) of the antibody did not influ-
ence the retinoid effects [19]. reflect alleviation of renal damage by retinoids. It is of
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note however, that even in the absence of renal injury, activator protein-1, or cyclins, or possibly suppression of
pro-proliferative growth factors [15]. Retinoids inhibitedretinoids lower blood pressure after chronic angiotensin
II (Ang II) infusion. We have shown that retinoids lower Ang II or endothelin-1, and -adrenergic-induced cell
growth in cardiac myocytes or vascular smooth muscleAng II type 1 (AT1) receptor binding in vascular smooth
muscle and abrogate the increase of glomerular AT1 cells [21, 45].
The reduction of the number of glomerular monocytesreceptor expression in the acute anti-Thy1.1-nephritis
model [21]. Angiotensin II contributes to renal damage and macrophages may be a further important aspect to
explain the beneficial effect of retinoids. Monocytes andin chronic glomerulonephritis induced by mAb 1-22-3
as shown by the beneficial effects of AT1 receptor block- macrophages contribute to glomerular damage. They are
sources of pro-inflammatory cytokines and growth fac-ade by candesartan [26]. These findings do not prove,
but suggest, that retinoids influence blood pressure not tors such as TGF-1 that contribute to the sclerosis in
this model [26]. Retinoids have anti-migratory propertiesonly indirectly by reducing renal damage, but also di-
rectly by interfering with the activity of the renin-angio- [3] and are involved in the monocyte/macrophage differ-
entiation process [46]. A reduction of glomerular ED-1tensin system.
The glomerulosclerosis index was markedly elevated () cells has been demonstrated in the acute phase of
anti-Thy1.1-nephritis. The present study in the chronicin vehicle-treated nephritic rats [26]. Isotretinoin reduced,
but failed to completely normalize, the glomerulosclero- model suggests (a) that monocytes/macrophages play an
important role in the chronic phase as well and (b) thatsis index. There were no significant differences between
high and low doses of isotretinoin indicating that the low retinoids interfere with this process.
The chronic model of mAb 1-22-3 glomerulonephritisdose is as effective as the high dose in treating renal
disease. This is of interest, since a dose of 2 mg/kg/day is characterized by an elevated expression of TGF-1, a
cytokine that is closely associated with the developmentof isotretinoin is in the range of doses that also are used
in humans for the treatment of skin diseases [41]. It is of glomerulosclerosis and interstitial fibrosis [27]. The
increase in renal TGF-1 and TGF receptor II genenot excluded that even lower doses would be effective,
potentially improving the benefit/side effect ratio. expression found in vehicle-treated nephritic rats was
almost normalized by retinoid-treatment. Retinoids haveIt is unlikely that in isotretinoin-treated rats the reduc-
tion of renal damage is only due to blood pressure low- a direct effect on TGF-1 gene expression via inhibition
of AP-1 [47], since the TGF-1 promoter contains threeering, since in the acute model of anti-Thy1.1-nephritis
renal damage was markedly less in retinoid-treated rats, AP-1 binding sites. Nevertheless, the effects of retinoids
depend on the cellular context, since in cell cultures bothwhere an effect of blood pressure on renal damage is
supposed to be of less importance. increased or decreased TGF-1 expression was seen un-
der the influence of retinoids [48]. In contrast, retinoidsThe lower glomerulosclerosis index probably reflects
the direct effects of retinoids on glomerular cell prolifer- consistently inhibit the Ang II-dependent increase in
TGF-1 gene expression in vascular smooth muscle cellsation and immigration of inflammatory cells. Isotretinoin
significantly reduced the total glomerular cell number. [21]. The reduction of TGF-1 gene expression in the
nephritic kidney may be due to a direct suppression ofAn antiproliferative action of retinoids has been demon-
strated in many cell types, which provided the rationale TGF-1 expression, but also may reflect to some extent
the lower number of monocytes and macrophages, sincefor the use of retinoids in oncology [2, 42]. Apart from
malignant cells, retinoids inhibit proliferation of mesan- these cells are prominent sources of TGF-1 [20]. Renal
expression of fibronectin-1 and pro-collagen-1 in the ne-gial, vascular smooth muscle and endothelial as well as
tubular cells [14, 21, 43]. Inhibition of vascular smooth phritic kidney was reduced after isotretinoin treatment,
reflecting the lesser degree of interstitial fibrosis andmuscle cell growth by retinoids was reported in resteno-
sis injury after balloon arterioplasty. In acute anti-Thy glomerulosclerosis. This also was indicated by the fewer
number of tubulointerstitial cells and a reduction in tubu-1.1 nephritis and in non-inflammatory kidney models
such as unilateral ureteral obstruction, antiproliferative lointerstitial lesions. This observation is in line with the
previous documentation of a possible antifibrotic actionactions were seen as well [19, 44]. The lower number of
glomerular cells in isotretinoin-treated kidneys is due, of retinoids [49].
In summary, we have established that in the rat mesan-at least in part, to inhibition of cell proliferation, since
isotretinoin treatment reduces the number of Ki67() gioproliferative glomerulonephritis model, retinoids in
doses used in human disease markedly reduce renal dam-cells. It is notable, however, that retinoids do not influence
the basal cell number in glomeruli as shown by the results age and normalize both glomerular and interstitial struc-
ture. The present study provides further evidence forin the control groups.
The mechanism of the antiproliferative action of reti- anti-inflammatory, antiproliferative and antifibrotic ac-
tions of retinoids in glomerulonephritis. Although thenoids has not been completely elucidated but probably
involves different pathways, such as interference with renal effects of retinoids and the mechanisms of their
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the actions of angiotensin II on vascular smooth muscle cells. Circaction have not yet been examined in detail, the thera-
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